gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Tuberous sclerosis 2

Mutations in this gene lead to tuberous sclerosis complex. Its gene product is believed to be a tumor suppressor and is able to stimulate specific GTPases. The protein associates with hamartin in a cytosolic complex, possibly acting as a chaperone for hamartin. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Tumor Suppressor, mTOR, mTORC1, Akt, CAN
Papers using TSC2 antibodies
Improved insulin sensitivity by calorie restriction is associated with reduction of ERK and p70S6K activities in the liver of obese Zucker rats.
Sandri Marco, In PLoS ONE, 2008
... Anti-GSK3α (#9338), anti-RPS6 (#2217), anti-TSC2 (3612), and anti-rabbit IgG-horseradish peroxide conjugate (#7074) were purchased from Cell Signaling Technology (Danvers, MA) ...
Generation of a conditional disruption of the Tsc2 gene
Sahin Mustafa et al., In Nature neuroscience, 2006
... phospho-4E-BP1 (T37/46), phospho-mTOR (S2481) (Cell Signaling), TSC2, EphA4, ephrin-A2, ephrin-A5, EphA5, Brn3b (H-18), (Santa Cruz), phospho-TSC2 (S664) (BioLegend), TSC1 (Zymed), TSC2 (Biosource), ...
Inositol 1,4,5-trisphosphate [correction of tris-phosphate] activation of inositol trisphosphate [correction of tris-phosphate] receptor Ca2+ channel by ligand tuning of Ca2+ inhibition
Stöckli Jacqueline et al., In The Journal of Biological Chemistry, 1997
... Polyclonal rabbit antibody raised against TSC2 and 14-3-3β was purchased from Santa Cruz Biotechnology, Inc ...
Papers on TSC2
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
Chen et al., Houston, United States. In Ann Oncol, Feb 2016
RESULTS: Of the 1000 patients who underwent sequencing, 43 had likely pathogenic germline variants: APC (1), BRCA1 (11), BRCA2 (10), TP53 (10), MSH2 (1), MSH6 (4), PALB2 (2), PTEN (2), TSC2 (1), and RB1 (1).
Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Stephens et al., Albany, United States. In Breast Cancer Res Treat, Feb 2016
CRGA were also found in 20 additional genes including PIK3CA (5), BRCA1 (1), TSC2 (1), STK11 (1), AKT3 (1), and ESR1 (1).
Multiple amino acid sensing inputs to mTORC1.
Hall et al., Basel, Switzerland. In Cell Res, Jan 2016
In mammals, growth factors and cellular energy stimulate mTORC1 activity through inhibition of the TSC complex (TSC1-TSC2-TBC1D7), a negative regulator of mTORC1.
Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir, Sydney, Australia. In Pharmacol Ther, Jan 2016
UNASSIGNED: Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease affecting predominantly young women.
Role of Prolactin Receptors in Lymphangioleiomyomatosis.
Norstedt et al., Stockholm, Sweden. In Plos One, Dec 2015
Pulmonary lymphangioleiomyomatosis (LAM) is a rare lung disease caused by mutations in the tumor suppressor genes encoding Tuberous Sclerosis Complex (TSC) 1 and TSC2.
Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex.
Curatolo et al., Roma, Italy. In Semin Pediatr Neurol, Dec 2015
In the last decades, there has been a great progress in understanding the pathophysiology of TSC-related manifestations, which are mainly linked to the hyperactivation of the so-called mammalian target of rapamycin (mTOR) pathway, as a consequence of the mutation in 1 of the 2 genes TSC1 or TSC2.
Genotype/Phenotype Correlations in Tuberous Sclerosis Complex.
Graziola et al., Roma, Italy. In Semin Pediatr Neurol, Dec 2015
TSC is caused by the mutation in one of the 2 genes TSC1, at 9q34, and TSC2, at 16p13.3.
Leukemia inhibitory factor (LIF) withdrawal activates mTOR signaling pathway in mouse embryonic stem cells through the MEK/ERK/TSC2 pathway.
Pospelov et al., Saint Petersburg, Russia. In Cell Death Dis, Dec 2015
LIF removal strongly activates ERK activity indicating that ERK can be involved in either direct phosphorylation of mTOR or phosphorylation of an upstream negative regulator of mTOR - TSC1/TSC2 proteins.
Transcriptome profiling in fast versus slow-growing rainbow trout across seasonal gradients.
Palti et al., Guelph, Canada. In Bmc Genomics, Dec 2015
They have elevated mitochondrial and cytosolic creatine kinase expression levels and appear to suppress mTOR-signaling as evidenced by elevated TSC2 expression, and they also have elevated p53 levels.
[Pulmonary lymphangioleiomyomatosis: From pathogenesis to management].
Cottin et al., Lyon, France. In Rev Mal Respir, Dec 2015
At the pathological level, the cellular proliferation found in LAM is in part due to the presence of mutations in the tumour suppressor genes TSC1 and TSC2 (Tuberous Sclerosis Complex).
Neurological and neuropsychiatric aspects of tuberous sclerosis complex.
de Vries et al., Roma, Italy. In Lancet Neurol, Jul 2015
Mutations in the TSC1 or TSC2 genes lead to disruption of the TSC1-TSC2 intracellular protein complex, causing overactivation of the mammalian target of rapamycin (mTOR) protein complex.
Response and acquired resistance to everolimus in anaplastic thyroid cancer.
Lorch et al., Cambridge, United States. In N Engl J Med, 2014
Whole-exome sequencing of pretreatment and drug-resistant tumors revealed a nonsense mutation in TSC2, a negative regulator of mTOR, suggesting a mechanism for exquisite sensitivity to everolimus.
Coordinated regulation of protein synthesis and degradation by mTORC1.
Manning et al., Boston, United States. In Nature, 2014
Genetic activation of mTORC1 through loss of the tuberous sclerosis complex tumour suppressors, TSC1 or TSC2, or physiological activation of mTORC1 in response to growth factors or feeding resulted in increased NRF1 expression in cells and tissues.
Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.
Manning et al., Boston, United States. In Cell, 2014
Insulin activates mTORC1 through the PI3K-Akt pathway, which inhibits the TSC1-TSC2-TBC1D7 complex (the TSC complex) to turn on Rheb, an essential activator of mTORC1.
Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2.
Teleman et al., Heidelberg, Germany. In Cell, 2014
We show here that, upon amino acid removal, the Rag GTPases also recruit TSC2 to the lysosome, where it can act on Rheb.
Tuberous sclerosis complex: genotype/phenotype correlation of retinal findings.
Singh et al., Cleveland, United States. In Ophthalmology, 2012
TSC2 mutations are more frequent in patients with retinal findings than in those without retinal findings.
Tsc2, a positional candidate gene underlying a quantitative trait locus for hepatic steatosis.
Attie et al., Madison, United States. In J Lipid Res, 2012
Tsc2 as a gene underlying the chromosome 17 NAFLD QTL
Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction.
Argani et al., In Am J Surg Pathol, 2012
Perivascular epithelioid cell tumors with TFE3 gene fusions demonstrated intact, robust tuberin protein labeling and no TSC2 loss of heterozygosity.
Identification of TSC1 and TSC2 mutations in Korean patients with tuberous sclerosis complex.
Ki et al., Seoul, South Korea. In Pediatr Neurol, 2012
This study presented that the mutation rate of the TSC1 and TSC2 genes in Korean patients with tuberous sclerosis complex was 100%.
TSC1/2 signaling complex is essential for peripheral naïve CD8+ T cell survival and homeostasis in mice.
Zhao et al., Beijing, China. In Plos One, 2011
TSC1 plays an essential role in regulating peripheral naive CD8(+) T cell homeostasis, possible via an mTOR-Akt-FoxO-Bim signaling pathway.
share on facebooktweetadd +1mail to friends